Financial reports
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
27 Apr 22
10-K
2021 FY
Annual report
14 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
15 Nov 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
8-K
Departure of Directors or Certain Officers
22 May 23
8-K
Regulation FD Disclosure
20 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Results of Operations and Financial Condition
9 Jan 23
8-K
Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement
5 Dec 22
8-K
Departure of Directors or Certain Officers
1 Dec 22
8-K
Material Modifications to Rights of Security Holders
27 Oct 22
Registration and prospectus
S-3
Shelf registration
13 Mar 24
S-8
Registration of securities for employees
13 Mar 24
S-3
Shelf registration
30 Jan 24
S-8
Registration of securities for employees
6 Jun 23
424B5
Prospectus supplement for primary offering
23 Mar 23
S-8
Registration of securities for employees
23 Mar 23
S-3
Shelf registration
26 Jan 23
S-8
Registration of securities for employees
9 Jan 23
D
$9.20 mm in equity, sold $9.20 mm, 13 investors
9 Dec 22
S-8
Registration of securities for employees
2 Dec 22
Proxies
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFM14A
Proxy related to merger
7 Nov 22
PREM14A
Preliminary proxy related to merger
28 Oct 22
DEFA14A
Additional proxy soliciting materials
30 Sep 22
DEFA14A
Additional proxy soliciting materials
30 Sep 22
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
PRE 14A
Preliminary proxy
15 Apr 22
Other
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
5 Feb 24
EFFECT
Notice of effectiveness
7 Feb 23
CORRESP
Correspondence with SEC
2 Feb 23
UPLOAD
Letter from SEC
1 Feb 23
EFFECT
Notice of effectiveness
30 Aug 21
CORRESP
Correspondence with SEC
25 Aug 21
UPLOAD
Letter from SEC
25 Aug 21
SEC STAFF
SEC staff action: Order
19 Apr 21